Share ownership Bright Minds Biosciences Inc.

DRUG

CA10919W4056

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 20:49:47 17/06/2026 BST			5-day change	1st Jan Change
84.72 ^CAD	0.00%		-2.91%	-23.28%

05-19	Bright Minds Biosciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026	CI
04-08	Certain RSUs of Bright Minds Biosciences Inc. are subject to a Lock-Up Agreement Ending on 8-APR-2026.	CI

Share class: Bright Minds Biosciences Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	9,812,061	8,677,077 ( 88.43 %)	0	88.43 %

Major shareholders: Bright Minds Biosciences Inc.

Name	Stocks	%	Valuation
Janus Henderson Investors US LLC 13.12 %	1,284,324	13.12 %	113 M $
Cormorant Asset Management LP 10.82 %	1,059,331	10.82 %	93 M $
Ian McDonald 10.27 %	1,004,900	10.27 %	89 M $
Cormorant Asset Management LP 9.707 %	950,000	9.707 %	84 M $
Vivo Capital LLC 5.693 %	557,172	5.693 %	49 M $
Braidwell LP 5.514 %	539,708	5.514 %	48 M $
BlackRock Advisors LLC 5.116 %	500,731	5.116 %	44 M $
Adage Capital Partners GP LLC 5.065 %	495,743	5.065 %	44 M $
Vestal Point Capital LP 5.03 %	492,319	5.03 %	43 M $
Driehaus Capital Management LLC 4.419 %	432,515	4.419 %	38 M $
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	93.95%
Individuals	13.75%
Others	8.17%
State Street Corp.	1.11%
SEI Investments Co.	0.11%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	101.77%
Individuals	13.75%
United Kingdom	1.13%
Australia	0.2%
Switzerland	0.14%
Norway	0.05%
Hong Kong	0.02%
Canada	0.02%
China	0.01%

Based on 1000 largest holdings

Bright Minds Biosciences Inc. is a biotechnology company, which is engaged in developing treatments for patients with neurological and psychiatric disorders. The Company is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The Company has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.

Employees

Sector

Biotechnology & Medical Research

More about the company